Silence Therapeutics to Participate in March Investor Conferences
Silence Therapeutics to Participate in March Investor Conferences
22 February 2021
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Company management will present business updates at two virtual investor conferences in March, details of which can be found below:
Cowen 41st Annual Health Care Conference
| Date: | Monday, March 1, 2021 | |
| Time: | 10:20 am EST (15:20 GMT) |
H.C. Wainwright Global Life Sciences Conference
| Date: | Tuesday, March 9, 2021 | |
| Time: | On-Demand |
Live webcasts of the presentations can be accessed via the Investors section of the Company's website at www.silence-therapeucs.com. An archived replay of the webcasts will be available on the Company's website following the conference.
Enquiries:
| Silence Therapeutics plc Gem Hopkins, Head of IR and Corporate Communications ir@silence-therapeutics.com | Tel: +1 (646) 637-3208 |
| Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence | Tel: +44 (0) 20 7597 5970 |
| European IR Consilium Strategic Communications Mary-Jane Elliott/ Angela Gray / Chris Welsh silencetherapeutics@consilium-comms.com | Tel: +44 (0) 20 3709 5700 |
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary messenger RNAi GOLD™ (GalNAc Oligonucleotide Discovery) Platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.
